Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$107.53 USD
+0.67 (0.63%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $107.69 +0.16 (0.15%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Price, Consensus and EPS Surprise
ABT 107.53 +0.67(0.63%)
Will ABT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ABT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ABT
Is ProShares S&P 500 Dividend Aristocrats ETF (NOBL) a Strong ETF Right Now?
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
ABT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Q1 Earnings Review
Markets Try to Shake Off April Blues
Abbott (ABT) Q1 Earnings Beat Estimates, Margins Contract
Other News for ABT
ABT, DHR, DXCM: Which “Strong Buy” Healthcare Stock Has More Upside?
ABT July 19th Options Begin Trading
3 Best Healthcare Stocks to Buy in April 2024, According to Analysts
Intelligent Bio Solutions’ Fingerprint Drug Screening Technology Poised For Massive Growth
Abbott Laboratories stock outperforms competitors despite losses on the day